Connect with us


FG to ban syringe importation, encourage local production



…As NAFDAC calls for holistic approach to combating illicit imports

The Minister of State for Health, Dr Tunji Alausa has called for a total ban on the importation of medical syringes into the country to encourage local production and help to grow the nation’s economy. The Director General of the National Agency for Food and Drug Administration and Control (NAFDAC), Prof. Mojisola Adeyeye reiterated the need for a holistic approach by all the relevant agencies of government to solve the problem of substandard falsified medical devices coming into the country through the ports.

The statements were made on Thursday during the official visit to the multi-billion Naira ultra-modern Afrimedical Manufacturing and Supplies Limited Syringe factory located within Karameh Industrial City, Arepo, Ogun State, by the Minister of State for Health, Dr Tunji Alausa, Minister of Industry, Trade and Investment, Mrs Doris Nkiruka Uzo-Anite, Minister of State for Youth, and Sports Development, Mr. Ayodele Olawande, Director-General of NAFDAC, Prof. Mojisola Adeyeye, United Nations Deputy Secretary General,  Dr. Mrs Amina Mohammed and the Chief Executive Officer, Nigeria Investment Promotion Commission (NIPC), Mrs Aisha Rimi.

The Health Minister reaffirmed the determination of the Federal Government to provide the necessary support to the local manufacturing sector to enhance its contribution to the Gross Domestic Product GDP.

Dr Alausa affirmed that the restructuring of syringe and needle production in Nigeria aims to guarantee the availability of high-quality products manufactured by Nigerians in the market to generate lucrative employment opportunities for Nigerians.

The minister, however, implored NAFDAC to ensure that unbridled importation of Syringe does not hamper the development of the local industry through unhealthy competition.

“Don’t give them any more authorisation to import. We need to protect the local industry through the backward integration model aimed at enhancing the local capacity,” he said.

The DG of NAFDAC, Prof. Mojisola Adeyeye, disclosed that the Agency had put an end to granting import authorisation to importers including the international partners.

According to her, the National Primary Healthcare Development Agency (NPHCDA) has also been directed to patronise the local manufacturers of syringes to provide employment opportunities to Nigerians through the expansion of operations of the Nigeria manufacturing companies. She added that the National Primary Health Agency was given the last import order in December 2023 with the instruction that they should begin to source from the local manufacturers thereafter.

She further explained that NAFDAC has halted syringe imports to promote locally made syringes. This suspension applies even to syringes previously imported by NAFDAC’s international partners. The goal is to shift the focus towards supporting domestic syringe manufacturing.

“However, for the local manufacturers, we are doing hand-holding with our Syringe companies. Hand-holding, meaning we are working with them by correcting whatever we found wrong or inappropriate in their operations, adding that this initiative has started yielding positive dividends as the World Health Organisation WHO recently requested for names of the three syringe manufacturing companies in Nigeria to do business with.”

She disclosed that the names were supplied to WHO and they have been contacted for guidance toward prequalification and eventual access of the products for use.

Prof. Adeyeye however, advocated for a holistic approach to combating the incidence of importation of Substandard Falsified medical devices into the country. She disclosed that some medical devices still come into the country with the aid of compromised officials at the ports. According to her, the government had already put high tariffs on the importation of syringes to discourage importation.

She, nevertheless, expressed regret that the system in the ports negates that policy.

“That is the problem. It’s going to be a holistic government approach to tackle the problem. It’s not something that only NAFDAC, SON, or Customs can do. It must be all-embracing.”

The NAFDAC boss however noted that the locally manufactured syringes may be costlier, she quickly added that once the local industry starts to have volume the price will come down.

She also urged the government to reduce the import tariff on critical raw materials and equipment used for local production, adding that they should be given zero tariffs for a limited time moratorium.

Prof Adeyeye said that NAFDAC has the power to create a ceiling on importation, adding that the three companies in Nigeria can produce syringes that will satisfy the local demand and still export.

The Minister further requested the NAFDAC DG to engage all the relevant agencies to achieve the desired government policy thrust as he reaffirmed President Bola Tinubu’s commitment to remove barriers impeding industrialisation and manufacturing in Nigeria.

The chairman of Mikano International, the parent company of Afrimedical Manufacturing and Supplies Limited, Mr. Mofid Karameh told the visiting top government officials and UN Deputy Secretary General that his company is poised to revolutionise the landscape with its aim to restore Nigeria as the premier hub in Africa.

He said the company boasts of an internationally accredited factory with an annual production capacity of 1.8 billion syringes, employing cutting-edge E-beam sterilisation technology.

Founded in 2019, he said Afrimedical has emerged as a prominent provider of medical solutions, delivering products such as 2ml, 3ml, 5ml & 10ml sterile hypodermic syringes, 0.5 ml auto-disable immunization syringes, face masks, and sanitizing tunnels.

Afrimedical Manufacturing and Supplies Limited, a division of Mikano International Limited manufactures hypodermic syringes and other healthcare products, providing solutions to Africa’s health needs and saving lives. Tailored to protect medical institutions and professionals in Nigeria and throughout Africa from virus-related infections, Mr. Karameh said these solutions showcase Afrimedical’s commitment to healthcare safety.

The Managing Director of Afrimedical, Mr. Akin Oyediran emphasised the company’s plans to manufacture high-quality syringes not only for Nigeria but also for some neighbouring countries. He added that the company uses 30 percent less plastic with high-quality medical-grade materials in its production.

He expressed gratitude for the Federal Government’s support, noting that the initiative to prohibit syringe imports will diminish the prevalence of substandard products in the Nigerian market and establish a conducive environment for local manufacturers in the pharmaceutical sector to flourish.


Over 1,800 malnourished kids recovered in six months in Bauchi — CSOs



Rauf Oyewole, Bauchi

The Coalition of Civil Society –Scaling Up Nutrition in Nigeria, Bauchi State Chapter has said that through its partnership with other implementing partners they have assisted over 1,800 malnourished children to recover from Severe Acute Malnutrition (SAM).

The Secretary of the Network, Dabis Mwalike while addressing journalists as part of the activities marking the 10th year anniversary of the network, said that it also engaged in preventive measures against malnutrition in the state.

According to her, during the implementation, 698 healthcare providers were trained across the 20 local government areas of Bauchi, 400 community-based volunteers were trained while 4,229 comprising 2,059 males and 2,170 females, children under five identified with SAM and 7,743 made of 3661males and 4082 females, children under five identified with Moderate Acute Malnutrition (MAM).

She added that 1,825 children under five identified with SAM and MAM recovered. While 202 PHCs established food banks.

She said that despite all the achievements, malnutrition remains a concern to public health and a threat to child survival, growth, and development in the country, and Bauchi State according to NNHS (2018) and NDHS (2018) the State stunting rate is 46 percent, wasting is 9.5 percent while underweight is 28.2 percent and overweight is 0.5 percent.

Continue Reading


Capacity training will reduce migration of health workers- NPHCDA



The National Primary Healthcare Development Agency (NPHCDA) says it is taking steps towards tackling migration of health workers through capacity training programmes.
Mr Julius Idoko, NPHCDA Coordinator in Cross River, said this at the opening of a five-day capacity training for 100 frontline healthcare workers in the state on Tuesday.
Idoko said that the training, a project of the Health Minister, Prof. Mohammad Pate, was aimed at improving the capacity of health workers and making migration out of the country less attractive.
”The rate at which health workers leave the country has become worrisome, this training is to build their capacities.
”This initiative is one of the steps we are taking to curb the continuous exodus of healthcare professionals from the country.
”If we continue to engage and improve the capacity of our health workers, there will be no reason for them to leave the country,” he said.
The cordinator said that the initiative targets to capture no fewer than 120,000 healthcare workers in public institutions across the country.
Also speaking, Dr Henry Ayuk, Cross River’s Commissioner for Health, described the training as ‘very important’ to the state following its peculiar challenges.
He said the training would strengthen the skills of healthcare workers and enhance their performances.
Ayuk said that the state government would equip no fewer then 450 primary health centres within the next one year to enhance healthcare delivery.
Dr Vivian Otu, Director-General, Cross Rivers Primary Healthcare Development Agency, commended NPHCDA for the initiative, describing it as timely and well-intended
He said thet those who benefited from the exercise would train others to ensure an active and efficient workforce.
The programme attracted participants from WHO, University of Calabar Teaching Hospital, President’s Malaria Initiative among others
Continue Reading


WHO targets immunisation of one million people, as Nigeria becomes first country to receive new meningitis vaccine



The World Health Organization (WHO) is targeting the immunisation of 1millikn persons as Nigeria becomes the first country in the world to roll out a new vaccine (Men5CV).

In a statement on Friday, WHO said that the vaccine would protect people against five strains of Meningococcus bacteria and described Nigeria’s feat as historic.

It said that health workers would begin an immunisation campaign aimed at reaching one million people.

The statement said that the vaccine and emergency vaccination activities are funded by Gavi, the Vaccine Alliance, which funds the global meningitis vaccine stockpile and supports lower-income countries with routine vaccination against meningitis.

According to the WHO, Nigeria is one of the 26 meningitis hyper-endemic countries in Africa, situated in the area known as the African Meningitis Belt.

It noted that in 2023, there was a 50 percent jump in annual meningitis cases reported across Africa.

“In Nigeria, an outbreak of Neisseria meningitidis (meningococcus) serogroup C outbreak, led to 1,742 suspected meningitis cases, including 101 confirmed cases and 153 deaths in seven of the 36 Nigerian states between October 2023 and March 2024.”

The states are Adamawa, Bauchi, Gombe, Jigawa, Katsina, Yobe, and Zamfara.

“To quell the deadly outbreak, a vaccination campaign was undertaken on March 25–28, 2024, to initially reach more than one million people aged 1-29 years,” it said.

The statement noted that meningitis is a serious infection that leads to the inflammation of the membranes (meninges) that surround and protect the brain and spinal cord.

“There are multiple causes of meningitis, including viral, bacterial, fungal, and parasitic pathogens.”

“Symptoms often include headache, fever, and stiff neck. Bacterial meningitis is the most serious and can also result in septicaemia (blood poisoning). It can seriously disable or kill within 24 hours,” the statement added.

It quoted WHO Director-General, Dr Tedros Ghebreyesus, as saying that meningitis was an old and deadly foe, adding that the new vaccine holds the potential to change the trajectory of the disease, preventing future outbreaks and saving many lives.

“Nigeria’s rollout brings us one step closer to our goal of eliminating meningitis by 2030,” Ghebreyesus said.

He said that the revolutionary new vaccine offers a powerful shield against the five major strains of the meningococcal bacteria – A, C, W, Y, and X – in a single shot.

All five strains cause meningitis and blood poisoning.

According to him, this provides broader protection than the current vaccine used in much of Africa, which is only effective against the A strain.

He said that the new vaccine has the potential to significantly reduce meningitis cases and advance progress in defeating meningitis.

“This is especially important for countries like Nigeria, where multiple serogroups are prevalent.

“The new vaccine uses the same technology as the meningitis A conjugate vaccine (MenAfriVac®), which wiped out meningococcal A epidemics in Nigeria,” the WHO boss said.

The statement quoted Prof. Muhammad Pate, Nigeria’s Minister of Health and Social Welfare, as saying that Northern Nigeria, particularly the states of Jigawa, Bauchi, and Yobe, were badly hit by the deadly outbreak of meningitis.

“This vaccine provides health workers with a new tool to both stop this outbreak and also put the country on a path to elimination,” Pate said.

According to him, Nigeria has done a lot of work preparing health workers and the health system for the rollout of the new vaccine.

“We got invaluable support from our populations in spite of the fasting period, and from our community leaders, especially the Emir of Gumel in Jigawa, who personally launched the vaccination campaign in the state.

“We’ll be monitoring progress closely and hopefully expand the immunisation in the coming months and years to accelerate progress,” he said.

The Minister said that the new multivalent conjugate vaccine took 13 years of effort and was based on a partnership between PATH and the Serum Institute of India.

“Financing from the UK government’s Foreign, Commonwealth, and Development Office was critical to its development,” he said.

Pate said that in July 2023, WHO prequalified the new Men5CV vaccine (which has brand name MenFive®), and in October 2023, it issued an official recommendation to countries to introduce the new vaccine.

According to him, Gavi allocated resources for the Men5CV rollout in December 2023, which are currently available for outbreak response through the emergency stockpile managed by the International Coordinating Group (ICG) on vaccine provision.

He added that the rollout, through mass preventive campaigns, was expected to start in 2025 across countries of the Meningitis Belt.

UK Minister for Development and Africa, Mr Andrew Mitchell, was also quoted as saying that the rollout of one million vaccines in northern Nigeria would help save lives, prevent long-term illness, and boost the goal of defeating meningitis globally by 2030.

“This is exactly the kind of scientific innovation supported by the UK, which I hope is replicated in years to come, to help us drive further breakthroughs, including wiping out other diseases,” Mitchell said.

He said that WHO has been supporting the Nigeria Centre for Disease Control and Prevention (NCDC) in responding to the meningitis outbreak in the country.

According to him, the areas of support include disease surveillance, active case finding, sample testing, and case management.

“WHO and partners have also played a vital role in supporting Nigeria to prepare for the rollout of the new vaccine and training health workers,” he said.

PATH’s Chief of Africa Region, Dr Nanthalile Mugala, was also quoted as saying that meningococcal meningitis had tormented countries across Africa year after year.

“The introduction of MenFive® in Nigeria heralds a transformative era in the fight against meningococcal meningitis in Africa.

“Building on the legacy of previous vaccination efforts, this milestone reflects over a decade of unwavering, innovative partnerships.

“The promise of MenFive® lies not just in its immediate impact but in the countless lives it stands to protect in the years to come, moving us closer to a future free from the threat of this disease,” Mugala said.

According to her, in 2019, WHO and partners launched the global roadmap to defeating meningitis by 2030.

“The roadmap sets a comprehensive vision towards a world free of meningitis and has three goals, including the elimination of bacterial meningitis epidemics.

Another goal is the reduction of cases of vaccine-preventable bacterial meningitis by 50 percent and deaths by 70 percent, as well as the reduction of disability and improvement of quality of life after meningitis, due to any cause.

Chief Programme Officer at Gavi, the Vaccine Alliance, Ms Aurélia Nguyen, was also quoted as saying that with outbreaks of infectious diseases on the rise worldwide, new innovations such as MenFive® were critical in helping the fight back.

She said that Vaccine Alliance funds the global stockpile as well as vaccine rollout in lower-income countries.

“This first shipment signals the start of Gavi support for a multivalent meningococcal conjugate vaccine (MMCV) programme which, with the required donor funding for our next five years of work, will see pentavalent meningococcal conjugate vaccines rolled out in high-risk countries.

“Thanks to vaccines, we have eliminated large and disruptive outbreaks of meningitis A in Africa, and now we have a tool to respond to other serogroups that still cause large outbreaks, resulting in long-term disability and deaths,” Nguyen said.

According to her, following Nigeria’s meningitis vaccine campaign, a major milestone on the road to defeat meningitis is the international summit on meningitis taking place in Paris in April 2024, where leaders will celebrate progress, identify challenges and assess next steps.

“It is also an opportunity for country leaders and key partners to commit, politically and financially, to accelerate progress towards eliminating meningitis as a public health problem by 2030,” she said.

Continue Reading